ClinicalTrials.gg
CompletedNCT04921280Updated Sep 29, 2021

Effectiveness of ICBT for Severe Health Anxiety in Clinical Psychiatry.

An observational study in Health Anxiety, Hypochondriasis and Illness Anxiety Disorder, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by Karolinska Institutet · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
456
Ages
16 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate the clinical effectiveness of internet-based cognitive therapy for severe health anxiety within regular psychiatric care.

A longitudinal cohort study will be conducted investigating 400 patients who have received ICBT for severe health anxiety between 2018-2020 in an outpatient psychiatric clinic providing Internet-based treatment.

The primary outcome measure will be the Short Health Anxiety Inventory, SHAI, and a within-group design with repeated measures will be used for primary analysis.

It is hypothesized that ICBT will be associated with a significant reduction in health anxiety as measured with SHAI, both after treatment and at six-month follow-up.

Read the detailed description

Severe health anxiety is a prevalent disorder, leading to considerable distress and is associated with high societal costs. Internet-based cognitive behaviour therapy is a method to improve access to evidence-based psychological treatments and it has shown to be efficacious in the treatment of severe health anxiety in several randomized controlled trials. However, there is limited knowledge of its effectiveness and application in clinical psychiatric care.

The aim of this study is to evaluate the clinical effectiveness of internet-based cognitive therapy for severe health anxiety within regular psychiatric care.

The investigators will conduct at a cohort-study with a pretest-posttest design investigating consecutively recruited patients from May 2018 to April 2021 in an outpatient psychiatric clinic specialised in delivering ICBT. The treatment content has been successfully tested in previous efficacy studies and will be delivered during 13 weeks. The primary outcome measure will be the gold standard SHAI and a within-group design with repeated measures will be used in the primary analysis. It is estimated that 400 patients will receive treatment during this period and thus be included in the study, if consenting.

It is hypothesized that ICBT will be associated with a significant reduction in health anxiety as measured with SHAI, both after treatment and at six-month follow-up. The effect size is expected to be somewhat smaller than in research trials but still moderate to large (d > 0.5).

02

Conditions studied

  • Health Anxiety
  • Hypochondriasis
  • Illness Anxiety Disorder
  • Somatic Symptom Disorder
  • Severe Health Anxiety
  • Hypochondriacal Disorder, Unspecified
03

In context

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients will receive treatment at the Internet Psychiatry Clinic (www.internetpsykiatri.se), Psychiatry Southwest, Karolinska University Hospital Huddinge. Patient can either apply for treatment through self-referral or through referral from primary or psychiatric care. Self-referred patients will register for treatment through a public e-service portal for health care (i.e.Vårdguiden; 1177.se).

Prior to treatment, patients will complete an online screening battery of self-report questionnaires and undergo an assessment by psychiatrists, or resident physicians supervised by psychiatrists.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 16 years of age
  • Living in Sweden
  • Primary diagnosis of hypochondriasis according to ICD-10
  • Able to read and write
  • Have access to a computer or other device with an Internet connection
  • If on medication, have a stable dose of psychotropic medication for 4 weeks prior to treatment
  • Not having other psychiatric difficulties (e.g., ongoing substance abuse or a psychotic syndrome) that makes ICBT an unsuitable intervention

Exclusion criteria

Exclusion Criteria:

  • Patients with severe depression (clinician rated Montgomery-Asberg Depression Rating Scale- Self-Rated; MADRS-S and/or moderate to high risk of suicide in which monitoring is required
  • Patients with low motivation, severe apathy, or difficulty concentrating
  • Patients with psychosis
  • Patients with untreated drug or alcohol problems
  • Patients with reading and/or writing difficulties, including language difficulties;
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
456 participants (actual)
Patient registry
No

Groups and cohorts

  • Treatment group

    Patients who have received treatment for severe health anxiety at the Internet Psychiatry Clinic, Psychiatry Southwest, Karolinska University Hospital Huddinge between April 2018 to April 2021.

    Behavioral: Internet based Cognitive Behavioural Therapy

Interventions

  • BehavioralInternet based Cognitive Behavioural Therapy

    The treatment program consists of 12 chapters or "modules" spread over 12 weeks and contains written information, different exercises and weekly homework assignment. Patients get access to the CBT program via an internet portal and they have weekly contact with a licenced psychologist via encrypted email. Focus of the therapist support is to review the content of the weekly module, reinforce progress and engagement in therapy and assist with treatment difficulties. If needed, therapist can contact patients via telephone. Patients receive weekly reminders via SMS to login to the portal and fill out self-report measures.

06

What researchers measure

Primary outcomes

  1. The short health anxiety inventory, SHAI

    A 14-item self-report measure of health anxiety severity. Total scores on the scale range from 0 to 42 with higher scores indicating a worse outcome (more severe symptoms of health anxiety).

    Time frame: Change from baseline (week 0) to post-treatment (week 12)

Secondary outcomes

  1. Montgomery Asberg Depression Rating Scale Self Rate, MADRS-S

    A 10-item self-report measure of depressive symptoms. Total scores on the scale range from 0 to 54 with higher scores indicating a worse outcome (more severe depressive symptoms).

    Time frame: Change from baseline (week 0) to post-treatment (week 12)

  2. Generalised Anxiety Disorder 7-item scale, GAD-7

    A 7-item self-report measure of general anxiety symptoms. Total scores on the scale range from 0 to 21 with higher scores indicating a worse outcome (more symptoms of general anxiety).

    Time frame: Change from baseline (week 0) to post-treatment (week 12)

  3. EQ5D

    A self-report measure of health-related quality of life.Total scores on the scale range from 0-1 with higher scores indicating a better outcome (more health and life quality). The questionnaire also includes a Visual Analog Scale (VAS) with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).

    Time frame: Change from baseline (week 0) to post-treatment (week 12)

07

Study locations

1 site
  • M46: Karolinska Universitetssjukhuset, Psykiatri Sydväst Stockholm, Huddinge, Sweden, 141 86
    Stockholm, 141 86, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Mar 2021, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
Jun 10, 2021
StartActual
Apr 1, 2018
Primary completionActual
Mar 15, 2021
CompletionActual
Mar 15, 2021
Last update
Sep 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04921280
Collaborators
Region Stockholm
Responsible party
Volen Ivanov (Principal investigator, Karolinska Institutet) — Principal investigator
First posted
Jun 10, 2021
Start date
Apr 1, 2018
Primary completion
Mar 15, 2021
Completion
Mar 15, 2021
Last update
Sep 29, 2021

Study contacts

Volen Ivanov, PhD
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion